Lonza News and Resources

Iconovo AB, an innovator in the development of inhalable drugs, has announced a collaboration with Lonza to develop a novel spray-dried formulation of an intranasal biologic aimed at treating obesity. This project marks the first step in Iconovo’s strategic initiative

Lonza, a global manufacturing partner for the pharmaceutical, biotech, and nutraceutical industries, has announced capacity expansions at its Rewari (India) and Suzhou (China) facilities. The additions include new manufacturing lines for hard gelatin capsules (HGCs), designed to support the production

Lonza has introduced its “One Lonza” strategy during its Investor Update 2024, focusing on the Contract Development and Manufacturing Organisation (CDMO) sector as its core business. The strategy includes a revised organizational structure aimed at streamlining operations, enhancing customer experience,

Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, has announced an extension of its service offerings to support the development of smart capsules for orally delivered biologic therapies. This expansion reflects the company’s commitment to addressing

Lonza, a global development and manufacturing partner to the pharmaceutical, has announced the completion of its first GMP product batch at its newly developed mammalian manufacturing facility in Portsmouth, US. This achievement marks a significant milestone in the company’s ongoing

Lonza, a global contract development and manufacturing organization (CDMO), is expanding its bioconjugation facility in Visp, Switzerland, to address the growing demand for antibody-drug conjugates (ADCs) and other bioconjugates. The company will invest in two new multipurpose 1,200L manufacturing suites,

Lonza has completed the expansion of its Drug Product Services (DPS) site in Basel, Switzerland, adding a new facility for quality control (QC) and bioanalytics. The 6000m² addition will support both clinical and commercial projects, allowing the company to increase

Lonza, one of the world’s largest healthcare development and manufacturing organizations, has completed its $1.2 billion acquisition of the Genentech large-scale biologics manufacturing facility located in Vacaville, California. This transaction marks a significant expansion of Lonza’s U.S. manufacturing capacity, enhancing

Acumen Pharmaceuticals has announced an extension of its partnership with Lonza to prepare for the future commercial launch of sabirnetug (ACU193), a novel therapeutic targeting Alzheimer’s disease (AD). Sabirnetug is the first humanized monoclonal antibody to selectively engage toxic soluble